At the International Association for the Study of Lung Cancer (IASLC) 2022 World Conference on Lung Cancer on August 8 in Vienna, Biodesix will present results showing that its VeriStrat liquid biopsy test can predict survival in patients with non-small cell lung cancer.
The blood-based test was predictive of progression-free survival and overall survival in patients with non-small cell lung cancer with low or negative PD-L1 treated with immune checkpoint inhibitors, the firm said.
Patients whose VeriStrat status results were VeriStrat Good had significantly greater progression-free survival and overall survival compared to the patients whose status was VeriStrat Poor, according to the company.
The test uses a proteomic signature identified using MALDI-ToF mass spectrometry coupled with machine learning.
